electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
Other Long-Term Assets
electroCore, Inc.
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Other Long-Term Assets
$274k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Other Long-Term Assets
$2.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Long-Term Assets
$4.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
27%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Long-Term Assets
$3.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Long-Term Assets
$16.5B
|
CAGR 3-Years
47%
|
CAGR 5-Years
50%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Long-Term Assets
$2.2B
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
29%
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
What is electroCore, Inc.'s Other Long-Term Assets?
Other Long-Term Assets
274k
USD
Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Other Long-Term Assets amounts to 274k USD.
What is electroCore, Inc.'s Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-48%
Over the last year, the Other Long-Term Assets growth was -75%. The average annual Other Long-Term Assets growth rates for electroCore, Inc. have been -61% over the past three years , -48% over the past five years .
You don't have any saved screeners yet